Drug Data Dents Metabasis
Metabasis Therapeutics (MBRX) fell more than 50% Tuesday on disappointing data from its type 2 diabetes candidate and a parting of ways with Schering-Plough (SGP) over hepatitis B treatment pradefovir.
The biopharmaceutical company said its phase IIb trial on CS-917 in patients with type 2 diabetes failed at its primary endpoint, significantly lowering a measure of glucose, in both doses tested.
"We are certainly disappointed with the CS-917 results, but we are hopeful that further review of the data will give us insight that will allow the continued development of this potentially important new approach for treating type 2 diabetes," said Metabasis CEO Paul Laikind, who noted in a conference call that the company has more questions than answers about the top-line results at this point.
"Although it certainly remains to be seen as we go through the data, I think most of the scientists who are familiar with the program here don't view this as a failed product," Laikind said, "They view this as a failed study."The investigative drug is being developed by Daiichi Sankyo pursuant to a licensing agreement with Metabasis. The companies said they are continuing to evaluate the data and that fasting blood sugar levels of patients at the start of the phase IIb trials were considerably lower than those in the phase IIa trials, so they're exploring whether this may have impacted the results.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV